Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity and Reactogenicity Study of a New Formulation of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children

NCT00611559 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00611559
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00611559 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity and Reactogenicity Study of a New Formulation of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children
Lead sponsor
GlaxoSmithKline
Phase
Phase 4
Overall status
Completed
Start date
February 14, 2008
Completion date
June 25, 2008
Enrollment
283 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acellular pertussis, diphtheria, hepatitis b, poliomyelitis, tetanus